SHZ · 300246.SZ
Guangdong Biolight Meditech Co., Ltd.
CN¥12.02-CN¥0.25 (-2.04%)
Guangdong Biolight Meditech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.31% below the high.
Loading market information…
SHH · 688393.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Guangzhou LBP Medicine Science & Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Guangzhou LBP Medicine Science & Technology Co., Ltd.’s forward annual dividend is CN¥0.10 per share, paid annual. The forward yield is 0.57% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Guangzhou LBP Medicine Science & Technology Co., Ltd.’s next earnings report is currently expected on Oct 31, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Guangzhou LBP Medicine Science & Technology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Guangzhou LBP Medicine Science & Technology Co., Ltd. specializes in the development and manufacture of innovative pathological diagnostic solutions for the Chinese market. Its comprehensive product portfolio includes advanced pathological diagnostic reagents and essential ancillary equipment. Among these are liquid-based cytology (LBC) offerings, encompassing both gynecological and non-gynecological series, complemented by specialized equipment. The company also provides fluorescence in situ hybridization (FISH) products, which are applied across a broad spectrum of conditions. These applications range from various cancers, including breast, bladder, lung, cervical, prostate, and thyroid, to other complex diagnoses such as neuroblastoma, soft tissue sarcoma, diverse solid tumors, prenatal screening, complications in abortion, oligodendrocytes tumors, lymphoma, multiple myeloma, and several forms of leukemia (chronic myelogenous, chronic lymphocytic, acute myeloid, and acute lymphoblastic), as well as myelodysplastic syndromes. Furthermore, GLBP offers immunohistochemistry (IHC) products, comprising a range of antibodies, advanced detection and repair systems, complementary products, and complete IHC kits. Additionally, its capabilities extend to molecular genetic diagnosis products. Established in 2005, Guangzhou LBP Medicine Science & Technology Co., Ltd. is headquartered in Guangzhou, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:30 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Oct 30, 2024 |
| CN¥0.14 |
| CN¥124.61M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥12.02-CN¥0.25 (-2.04%)
Guangdong Biolight Meditech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.31% below the high.
CN¥22.64-CN¥0.48 (-2.08%)
Guangzhou Jet Bio-Filtration Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 25.96% below the high.
CN¥7.31+CN¥1.22 (+20.03%)
Improve Medical Instruments Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.78% below the high.
CN¥7.70-CN¥0.16 (-2.04%)
Jiangsu Nanfang Medical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.89% below the high.
CN¥3.53-CN¥0.23 (-6.12%)
Chengdu Huasun Technology Group Inc., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.46% below the high.
CN¥5.56-CN¥0.19 (-3.3%)
Hubei Guangji Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.64% below the high.
CN¥5.98-CN¥0.10 (-1.64%)
Anhui Huangshan Capsule Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.63% below the high.
CN¥19.86-CN¥0.74 (-3.59%)
AVE Science&Technology CO.,LTD’s quoted price sits in the lower half of its reported 52-week range, 33.31% below the high.
